Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1452W HIGH $3.23
Volume
15.72 K
Value Traded
56.66 K
Short % Float
0.9%
-12.15%Week
-31.39%1 Month
+444.93%3 Month
+681.38%6 Month
-99.37%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.61 M
EPS (TTM)
-8.01
P/E Ratio
-
Ent. Value
-981.15 K
Total Shares
1.38 M
Float Shares
1.29 M
Insiders
6.74%
Institutions
13.83%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
BRTX Catalyst Timeline
Dated clinical, regulatory and corporate events for BioRestorative Therapies, Inc.
Past FDA Catalysts and PDUFA Decisions
How BRTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-06 | BRTX-100 (autologous cultured mesenchymal stem cells) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D20 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 94%
Micro Cap(rank 619 of 658)
Percentile Rank
BioRestorative Therapies, Inc. faces pipeline headwinds (20/100), with $185M risk-adjusted pipeline value, led by BRTX-100 in Lumbar Disc Disease (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BRTX-100 Monoclonal antibodyNCT04042844 | Lumbar Disc Disease | Phase 2 | RECRUITING | 99 | Dec 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every BRTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BRTX-100 Fast Track | chronic lumbar disc disease | Phase 2 | 2026-05-07 | 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measuresRead More | BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc DiseaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Broadrick Dale10% Owner | Sell | -1,112 445,933 held | $1.58 | 10/28/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in BRTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BRTX for Q2 2026. | ||||
BRTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BRTX ranks across every disease it competes in
Competitive Position is a premium feature
See how BRTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBRTX News
BRTX▼ -28.8%on this news
BioRestorative Therapies Announces Reverse Stock Split
BioRestorative Therapies, Inc. announced a 1-for-20 reverse stock split to comply with Nasdaq's minimum bid price requirement. The split will reduce the number of shares from approximately 27.6 million to about 1.38 million, effective September 7, 2026. The company aims to stabilize its stock price and maintain compliance with listing standards.
Read more →BRTXBioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform
BioRestorative Therapies has successfully completed the manufacturing of BRTX-100 for its Phase 2 clinical trial, a significant milestone for the company. This achievement highlights the strength of its integrated regenerative medicine platform, which allows for high-quality biologic production. The company aims to advance its regenerative biologics across therapeutic and aesthetic markets, improving operational costs and margins.
Read more →BRTXBioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth
Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative me
Read more →BRTX▲ +20.1%on this news· ran to +130% by day 3
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment MELVILLE, N.Y., May 26, 2026 (GLOBE NEWSWIRE) -- BioRestorative Th
Read more →BRTXBioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
BioRestorative Therapies presented new preclinical data at ISCT 2026, showcasing the distinct functional signatures of MSC-derived extracellular vesicles. The findings suggest targeted therapeutic applications across regenerative medicine and aesthetics. The company aims to align biological functions with clinical outcomes, enhancing its BioCosmeceutical platform for skin health and recovery solutions.
Read more →BRTX▼ -8.1%on this news· ran to -19% by day 3
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety signals observed MELVILLE, N.Y., May 07, 2026 (GLOBE NEWSWIR
Read more →BRTX▲ +11.6%on this news· ran to +26% by day 3
BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
Data demonstrate progress in each of its MSC-derived programs MELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq: BRTX), a late-stage clinical regenerative medicine company focused on stem cell-b
Read more →BRTX▼ -7.8%on this news
BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform
Collaboration establishes an independent clinical validation pathway, expands access to influential physician networks, and strengthens the foundation for possible broad commercial growth across professional, biologic dermal, and consumer channels MELVILLE, N.Y., April 21, 2026
Read more →BRTXBioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform
Partnership to drive brand architecture, go-to-market execution, and global launch of the Company’s product portfolio bridging biotechnology and premium skincare MELVILLE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “
Read more →BRTX▼ -10.9%on this news
BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal stem cells Presented at the 2026 Orthopaedic Research Society Annual Meeting MELVIL
Read more →BRTX▲ +11.9%on this news· ran to +28% by day 3
BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company’s proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th at the 2026 Orthopaedic Research Society Annual Meeting MELVILLE, N.Y., March
Read more →BRTXBioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026
BioRestorative Therapies, Inc. will participate in the Be+Well Beauty and Wellness Show in New York City from March 8-10, 2026. The event aims to expand awareness and distribution of its BioCosmeceutical platform, which utilizes regenerative biologics technology. The company seeks to engage with potential partners and showcase its innovative skincare solutions. This participation is part of a broader strategy to enhance commercialization efforts and clinical pipeline advancements.
Read more →BRTXBioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy
BioRestorative Therapies, Inc. has reported significant progress, including the completion of its Phase 2 trial enrollment for BRTX-100 and a positive FDA Type B meeting outcome. The company is also advancing its BioCosmeceutical platform and has strengthened its capital position through a recent public offering. These milestones position BioRestorative for potential growth and regulatory clarity in the coming years.
Read more →BRTX▲ +37%on this news
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs
BioRestorative Therapies has received patent approval in Australia for its ThermoStem technology, which utilizes brown adipose-derived stem cells to address obesity and metabolic disorders. This patent enhances the company's competitive edge against GLP-1 drugs. CEO Lance Alstodt emphasized the importance of this development in strengthening their global patent portfolio and advancing their mission in regenerative medicine.
Read more →BRTX▼ -6.3%on this news· ran to -23% by day 3
BioRestorative Announces Closing of $5.0 Million Public Offering
MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the closing of its
Read more →BRTX▼ -40.5%on this newsshared move
BioRestorative Announces Pricing of $5.0 Million Public Offering
BioRestorative Therapies, Inc. has announced a public offering of 14,285,715 shares at $0.35 each, aiming to raise approximately $5 million. The proceeds will be allocated to clinical trials for BRTX-100, pre-clinical research for the ThermoStem Program, and general corporate purposes. The offering is expected to close on February 13, 2026.
Read more →BRTX▼ -35.4%on this news· ran to -62% by day 1shared move
BioRestorative Announces Positive Outcome from Type B Meeting with FDA
BioRestorative Therapies announced a positive outcome from a Type B meeting with the FDA regarding its BRTX-100 program for chronic lumbar disc disease. The FDA's feedback supports a potential expedited Biologics License Application approval pathway. The company plans to submit a Phase 3 IND application in the latter half of 2026, highlighting the program's promising safety and efficacy data.
Read more →BRTX▼ -38.9%on this news· ran to -73% by day 3shared move
BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease
BioRestorative Therapies has completed patient enrollment in its Phase 2 trial for BRTX-100, targeting chronic lumbar disc disease. With 99 patients enrolled at 15 clinical sites, this trial is among the largest in its category. The study aims to assess both safety and efficacy through a randomized, double-blind design. Positive preliminary data has been shared at leading scientific conferences, paving the way for potential Phase 3 development.
Read more →BRTX▼ -6.8%on this news
BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease
MELVILLE, N.Y., Nov. 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it has been granted a Type B meeti
Read more →BRTX▼ -9.4%on this newsshared move
BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
BioRestorative Therapies reported its third quarter 2025 financial results, showing a revenue of approximately $11,800, a decrease from $233,600 in Q3-2024. The company experienced a net loss of $3.0 million for the quarter, higher than the previous year's loss. Despite these challenges, the CEO expressed optimism about future growth opportunities in clinical development and the BioCosmeceutical platform.
Read more →About BioRestorative Therapies, Inc.
Headquarters40 MARCUS DRIVE, MELVILLE, NY, 11747
BIOPHARMAWATCH ELITE PLUS
Trade the next BRTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime